Richard Garfein

Richard S. Garfein is a professor in the Division of Global Public Health, Department of Medicine, UC San Diego. He trained as an infectious disease epidemiologist, first earning an MPH from the San Diego State University School of Public Health in 1989 and then a PhD from Johns Hopkins University School of Hygiene and Public Health in 1997.

Between his graduate training and joining the UC San Diego faculty in 2005, Dr. Garfein served as an epidemic intelligence service officer in the Division of Viral Hepatitis and a senior staff epidemiologist in the Division of HIV/AIDS Prevention at the Centers for Disease Control and Prevention.

Garfein's research interests involve identifying risk factors for and developing interventions to prevent infectious diseases associated with substance abuse. While at the CDC, he investigated outbreaks of hepatitis B and C virus infection and led observational and interventional studies of HIV and viral hepatitis among injection drug users in the United States and abroad. Dr. Garfein has conducted studies describing HIV and HCV risk among IDUs and other marginalized populations in the US/Mexico border region. He is also conducting research on the behavioral determinates of acute HIV infection and public health policies related to HIV testing and non-prescription syringe sales.

Dr. Garfein has recently expanded the scope of his research to include describing tuberculosis among vulnerable populations, evaluating molecular assays for rapid detection of drug resistant TB, and developing mobile phone based interventions for improving patient adherence to anti-TB treatment. His international research and consulting activities have included Mexico, Russia, Thailand, Taiwan, Okinawa, Puerto Rico, Malawi, Sierra Leone and Kyrgyzstan.

  • HIV/AIDs prevention
  • Infectious diseases
  • Substance abuse
  • Tuberculosis

Falzon D, Timimi H, Kurosinski P, Migliori GB, Van Gemert W, Denkinger C, Isaacs C, Story A, Garfein RS, do Valle Bastos LG, Yassin MA, Rusovich V, Skrahina A, Van Hoi Le, Broger T, Abubakar I, Hayward A, Thomas BV, Temesgen Z, Quraishi S, von Delft D, Jaramillo E, Weyer K, Raviglione MC. Digital health for the End TB Strategy: developing priority products and making them work. The European Respiratory Journal. 2016;48(1):29-45.

Story A, Garfein RS, Hayward A, Rusovich V, Dadu A, Soltan V, Oprunenco A, Collins K, Sarin R, Quraishi S, Sharma M, Migliori GB, Varadarajan M, Falzon D. Monitoring therapy compliance of tuberculosis patients by using video-enabled electronic devices. Emerging Infectious Diseases 2016;22(3):538-540.

Garfein RS, Catanzaro DG, Rodwell TC, Avalos E, Jackson RL, Kaping J, Evasco H, Rodrigues C, Crudu V, Lin SY, Groessl E, Hillery N, Trollip A, Ganiats T, Victor TC, Eisenach K, Valafar F, Channick J, Qian L0, Catanzaro A. Phenotypic and genotypic diversity in a multinational sample of drug-resistant Mycobacterium tuberculosis isolates. International Journal of Tuberculosis and Lung Disease. 2015;19(4):420-7. PMCID: PMC4494864.

Robertson A, Garfein RS, Wagner KD, Mehta SR, Magis-Rodriguez C, Cuevas-Mota J, G, Gonzalez Moeno-Zuniga P, Strathdee SA. Evaluating the impact of Mexico’s drug policy reforms on people who inject drugs in Tijuana, B.C., Mexico, and San Diego, CA United States: A binational mixed methods research agenda. Harm Reduction Journal, 2014;11:4. PMCID: PMC3944401

Baird SJ, Garfein RS, McIntosh CT & Özler B. Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomized trial. Lancet. 2012. doi:10.1016/S0140-6736(11)61709-1


Affiliated Researchers